It's a scam from top to bottom. Nobody looks at the economics of healthcare and says it's working well.
So, in the past two years, estrogen patch prescriptions have nearly tripled.
It was hundreds of dollars.
For a simple tube, and you were selling it for 13.45 or something.
Shows you our markup's only 15%.
It's on short supply because money.
Yes. If it's harder to get, you can price it more.
These middlemen too big to care. Don't give a... My next dollar is not going to change my life, but my next dollar might save somebody's life.
Less than 9% of NIH grant money went to women's health over the last decade. Why do you think that is?
It's run by men. What was truly missing was and is trust. And I'll give you the craziest example and that's how I found out about the Ever Limus.
The views and opinions expressed on Unpaused are those of the talent and guests alone and are provided for informational and entertainment purposes only. No part of this podcast or any related materials are intended to be a substitute for professional medical advice, diagnosis, or treatment.
Every time I post about what medication costs on social media, my comment section explodes. One woman pays $14 for her estrogen patch. The next one pays 90. Same drug, same dose, same country. And underneath almost all of it, the same question, asked a hundred different ways: Why isn't the cost consistent? Two women can be handed the same prescription on the same day and pay wildly different prices. And neither of them can understand why. That is not an accident. It's how the system was built. And lately, a lot of you can't get your estrogen patch at all at any price.
Here's why it's so confusing. Between your doctor and your pharmacy sit a handful of middlemen. Between drug companies and your health insurance, they're the ones negotiating medicine prices and deciding which drugs your insurance will cover. My guest, Mark Cuban, is an entrepreneur and investor many of you may know as one of the sharks from Shark Tank. He has built and run many different types of companies including the Mark Cuban Cost Plus Drug Company. He co-founded the company in January of 2022 and spent four years inside the machinery of how drugs get priced, bought, and distributed in this country. With the Mark Cuban Cost Plus Drug Company, he did the thing this industry treats as radical. He published the price of each medication with transparent pricing and a limited markup. It's all right there on his website. And today we're going to talk about how this has fundamentally changed the pricing of medications in the United States. I'm Dr. Mary Clifton, a board-certified obstetrician and gynecologist and certified menopause practitioner and adjunct professor at the University of Texas Medical Branch. Welcome to Unpaused, the podcast where we cut through the silence and talk about what it really takes for women to thrive in the second half of life. This podcast is sponsored by Midi Health, the first virtual clinic created for women by women for the treatment of menopause. Don't let anyone tell you menopause is something you have to suffer through alone. Midi can help. Visit joinmidi.com to learn more. Mark Cuban, welcome to Unpaused.
So, I'm excited to have you on the show mostly because you are a problem solver and we have big problems in women's health and the supply chain for our estrogen patch, which I brought mine in today. Um, what are you doing differently with Cost Plus Drugs versus me going to CVS or Walgreens?
So it's costplusdrugs.com is our site where what makes us different initially is when you go, we show you our actual cost. When you put in a drug, whatever it may be, and it comes up, we'll show you what our cost is, what our markup is, and that typically means we're going to sell it for less than everybody else. So that's our initial goal, to make sure it's affordable, because it doesn't matter if it's available if you can't afford it, right? And so affordability is a key for us. Transparency is a key for us. But like everybody else, we're very aware that there's a shortage of a lot of HRT therapies. And so what we've done is rather than having one vendor, or sometimes we'll have two, but typically one vendor, we've gone out and sourced every source that we possibly can find. We've gone to the two major manufacturers and said, 'Look, we will take every unit of inventory that you're able to give us.' And it's crazy because we still can't keep up. We thought, okay, we have enough inventory. Are we going to be able to sell it all? And it just flipped completely around. And because of that, the two primary vendors that we use have completely different pricing.
And so we made the conscious decision to say even if we run out of inventory of the less expensive one, we're going to explain to people that look, we want to make sure that there's inventory available. Our most expensive version is still less expensive than most retail. So, we'll make that available to you and you'll have the choice of ordering, you know, the more expensive one or waiting for the less expensive one. And because we wanted the availability, because both prices are better than typical. Um, and that's worked for us so far. We still run out every now and then, but literally we are trying to buy up everything we can. If we were able to manufacture it, we would, but because it's the patches, it's a lot more difficult. We're not geared to do that. And we've gone to some of the manufacturers and we've literally asked if we can buy out their entire volumes.
All right. Hormonal medication. So in the past two years, estrogen patch prescriptions have nearly tripled. So this whole menopause gold rush...
And our volume is up far more. At least 10x.
Yeah. I mean it went, I don't know when the trigger point was, when the rules changed, but all of a sudden I was like, 'Oh my god, we're out of stock.'
Black box warning was one watershed moment, you know, that people were less scared to go get their prescription filled and doctors are getting more comfortable prescribing it. Um, but I think it's 44% of all estrogen scripts are now the patch specifically. Why do we have specifically a patch shortage versus oral estrogen shortage?
Oral is really easy to make. The patches require specialty manufacturing. If I could just gin up a manufacturing plant that could do the patches... Yeah, because it would take five years. No, I don't know, five years, but it's going to take a period of time.
So, demand for the patches at least tripled in two years, but the supply didn't, right? Did no one see this coming or...
No, they didn't care. Yeah. It's not that they didn't care, right? I don't think people really, you know, once a drug goes generic, just the way it's dealt with. Economics. Yeah. The economics are completely different and the manufacturers who had been making it, you know, if the numbers are the same for years, you don't anticipate that all of a sudden it's going to change. Um, and then it did and now they're responding and they're adding capacity. Um, but they were forced to, I think. Um, well, they could have raised the prices, but they chose to add capacity and we really tried to push them to that.
Um, there was a letter-writing campaign to the FDA when women couldn't find their patches. First on the website, on the FDA website, it would say there's no patch shortage, everything's fine, everything's fine. But like millions of women are on social media screaming that they can't get their patches. And um, then finally just in the last week, the FDA wording changed on the website that they're working with six manufacturers to try to, you know, encourage them to... What happens when we run out of stuff? Like how does the FDA get involved?
I think they can approve manufacturing plants or expansions more quickly. Okay. And that's a help, but it really just is how quick is the acceleration of demand. Okay? Because it's one thing to say we're going to make more, but if you make, you know, more for twice the demand thinking you're capturing everything, but you know, the acceleration rate because women are getting more comfortable and doctors are, is five times that, you're going to be behind no matter what. And I think that's what we really ran into. It wasn't a lack of interest. It was more, oh my god, that... at least that's what it was for us. It was, okay, Estradiol, okay, it's going up the sales charts right now. It's a big hit and what can we get? What do you mean that's all we can get? You know, and okay, we'll add manufacturers and we'll keep on just adding manufacturers wherever we can. But it was just the demand just outstripped the supply far more than they could add supply.
The demand isn't going to go down. No, for menopause hormone therapy. I only predict it getting increasingly... We had about 40% of women who were eligible on hormone therapy. We're still less than 10% right now. Yeah. So...
But literally we've tried to buy manufacturers. I've tried to buy a manufact... [laughter] I get it, right? I see it in my family. Trust me.
My husband jokes we should buy an estrogen patch factory and it's a... we're kidding. We have no, you know, no real plans to do that.
No, but I would if I could. Yeah. And to build one is just not a simple task. Um, but we discussed it and, you know, it wasn't something we could do, but we're looking to try to pre-buy as much of people's inventories as we can.
Would it be easier to make the gels or the sprays? Yes, I think it would be, but they're still under patent. Like, why don't we have a generic for those yet?
Because of the patent. Okay. Okay. I don't know the exact dates they come out of patent, but you can look those up real easy.
Yeah. All right. So, I want to walk our listeners through this. So, I'm on your website right now. Okay. And uh, this is the Dotti estradiol twice weekly. That's basically this generic. You know, this is the generic patch I have here in my hand. And on video, we're going to fly in the actual images from the website. So, your drug price with us, $39.18. That's just slightly higher than... I think that's the more expensive price, but it's not really that much more. I think it was like 25 before. So, and you have in stock the .05 and the 0.1, which are the two most commonly prescribed ones. So, yay. Um, so you save $146.69 on your medication. And here's why. I love how you say this. So, retail price at other pharmacies. Now, is this the retail price for the brand name?
No, this is the generic. It's the generic, but there's a standardized price called NADAC and that's what we use to determine... okay, because if you just walk into a pharmacy as a cash pay, in most retail pharmacies, that's what they'll charge you without like a GoodRx coupon or something. Even with, sometimes.
Okay, so manufacturing price, this is your price that you paid the manufacturer, was $29.72. Your 15% markup, which is your markup across the board, was $4.46. Pharmacy labor, so to go get that filled, and you know, $5, and then the standard shipping, $5.25. That's where we get our $39.18 from. So this person saved $146.69 had I not just gone to whatever pharmacy, walked in and paid the price without my insurance. Where is that $146 going?
It's not going to us. I mean, that's when I mentioned earlier... when I throw my credit card down, where's that delta going? Who's profiting? Okay. So, it's like some pharmacies. So, you're saying if I bought it for 146, where's that money? Oh, into the pocket of the pharmacy.
So, take me back to 2022 when you started the company. Why? Why did you do this?
Because nobody looks at the economics of healthcare and says, 'It's working well.' And specifically for pharmacy, um, we've all heard the stories of somebody walking into a pharmacy, waiting in line, getting to the counter, and realizing they don't have enough money or it costs more than they expect. And it's horrific. It's tragic. And that was the motivation. There are drugs that nobody knew the price to, that to this day, unless you're going to Cost Plus Drugs or maybe, you know, GoodRx in some cases, you have no idea what a medication costs. And if you don't have insurance or if you're high deductible, that can create all kinds of economic problems for you and obviously health problems if you can't afford it. So, we wanted to be completely transparent because what was truly missing was and is trust. Yeah. And I look at our primary product at costplusdrugs.com as being trust. And really to me, it's a formula where trust equals transparency divided by self-interest. And we're the only pharmacy anywhere in the world where you can go to our site and it shows you what our actual cost is. That's about as transparent as you can get. And it shows you our markup's only 15%, which is about as little self-interest as somebody can afford to do and still stay in business. And so because of that, we really focused on trust. We started, we launched January 19th of 2022 with 110 drugs. Now we're to thousands of them.
So, let's start with the basics for our listeners. Um, how does the current prescription drug price model work? Like, take what you're doing out of it. Take me back to 2021.
Right. Typically, right? So, typically people have insurance of one form or another. You may have Medicaid, you may have Medicare Advantage, you may have Medicare, you know, with Part D, then you may have it from your employer. And so, typically, you have a plan that you're part of and you know for the given medications that you take what your cost out of pocket is going to be, typically, not always. So if it's, you know, an inexpensive generic, it might be $5 or $10 or whatever. Um, if it's what they call a specialty generic, which is still just a pill, right, but they use it as an excuse to increase the price, you might have a coinsurance which might cost you $25, $50, or if it's a cancer drug or, you know, everolimus or something, might be more than $100 that you're paying out of pocket. And then either the taxpayers or your employer covers whatever the balance may be. That's typically how it works for most people then and today.
Talk to me about tiers. You know, as a healthcare consumer myself, besides being the person writing the prescriptions, I can remember like trying to help. Patients would bring in paperwork and like sitting there with them trying to figure out what their out of pocket would be. And like I have 15 minutes maybe with a patient, 10, you know, if it's not a well-woman exam. And you know, for me to sit there and help them go through the paper to figure out the pricing to help them and then source the pharmacy where they're going to get the best deal was... we just don't have time.
Yeah. I mean, it's not cost-effective for anybody and it's maddening because you want to spend more time with patients, but what good was your time if they can't get access to the med, right? And so, typically that's all part of the plan that they chose, right? Because, you know, there's open enrollment and your employer, whoever, and you go through that whole process. And you know, to their credit, for the most part, there's apps where you can go and look up the medication and it'll tell you at the patient side, not on the doctor's side, right? Real-time pharmacy benefits offered through, you know, through Epic or whoever is hard to come by right now. And they're actually trying to improve that so that doctors can have more say in what's going on. But really, it comes down to people just thinking it's going to be done the way it's always been done. You know, I chose this plan. This is what I thought would happen. And unfortunately, sometimes they change the plans and the rules of the plans, you know, midstream, but that's typically the way it works.
How did you spread the word about this? I found out about it on social media. I saw a clip of you talking about something and then I got curious, went to the website, and I couldn't believe, and I think you had just gotten it on formulary, how cheap vaginal estrogen was. Yeah. And this was right when the GSM guideline, the genitourinary syndrome of menopause guidelines were coming out and we were preaching from the rooftops but patients couldn't afford it. It was hundreds of dollars. Yep. For a simple tube and you were selling it for $13.45 or something and I just couldn't believe it.
Yeah. And that's because we're cost plus. Literally, we go out there and we find quality manufacturers. Um, and there's some things we manufacture ourselves, but they're more injectables than tubes, creams or pills. But we go out there and find a quality manufacturer and then we negotiate and whatever price we're able to get, we show it and mark it up just 15%. But the better news is as our volumes go up, and our volumes have really skyrocketed lately, um, our cost goes down and that means the cost to the patient goes down as well. And in terms of spreading the word, right? Initially it was just my big mouth, right? I have a platform and I get out there and I talk about it, social media, TV shows, whatever it may be. Um, but we don't spend any money on marketing. We made the conscious choice that we'd rather be able to sell the medications for less because you never know when that threshold is, right, where above this amount they can't afford it. So rather than spending money on marketing and advertising like a lot of the people in the company wanted to do, I was like, 'No, you don't understand.' When somebody, you know, a cancer drug like um, imatinib, right? If somebody was paying $900 or looking at paying $900 and our price was $34, they're going to be happy. A, they're going to tell their doctor, tell their friends, right? And they're going to tell their friends. They're going to go on the Facebook groups, the social media groups, and everybody else who has a similar condition. They're going to say, 'Hey, go check out Cost Plus Drugs.' So, we went from launching in January '22 to now having millions of people we've helped.
So, I found a quote where you said, 'The prescription drug industry is the easiest industry you've ever disrupted.' Yeah. Why is that?
Because it's really, really simple, right? What's the price? How much does it cost? What's the price? Who pays for it? And if that person can't pay for it, who helps them? Okay, that's it. And we made it clear of what the price is. And we deal with cash. We deal with some insurance companies through some PBMs, but mostly we just try to make it so it's as simple as possible. You just go to costplusdrugs.com. You sign up, you find the med, you put in your credit card, you tell your doctor where to send it, and that's it.
I've done it online and showed people how to do it.
I appreciate that. Thank you. [laughter]
So, especially for the vaginal estrogen. So, let's go back talking a little bit more about disparities and drug pricing. Um, I'm on social media a lot. I do a lot of education around menopause and a few months ago we were talking about how long did it take you to get your prescription for hormone therapy and then what was prescribed to you and what did you pay. And there were thousands of comments and women really shocked by the differences and what they were paying. So, one woman was paying, you know, $25 for her box. Um, hers happened to be covered by... that was her co-pay, right? Another woman it was well over $100. And so why is that?
So the co-pay is obvious, right? She's paying her insurance premiums and even then your co-pay might still be more expensive than a cash out-of-pocket price. Sure. But at the same time, if you walk into a retail pharmacy, they're trying to make as much money as possible, you know, especially if it's part of a big conglomerate. You know, a lot of these big huge healthcare conglomerates are too big to care.
Welcome back to another Midi Pause. I'm Dr. Mary Clifton, host of Unpaused. Let's talk about a menopause symptom that affects millions of women, but still doesn't get nearly enough attention. Genitourinary syndrome of menopause, also known as GSM. Now, that may sound like a complicated medical term, but GSM refers to a group of symptoms that can affect the vaginal and urinary systems during and after menopause. And the reality is it's incredibly common. Symptoms can include vaginal dryness, irritation, burning, painful sex, urinary urgency, frequent urinary tract infections, or feeling like you constantly need to use the bathroom. And unlike hot flashes, which often improve over time, GSM symptoms can actually worsen if left untreated. One of the reasons you may not have heard about GSM is because not enough women, and sadly some doctors, know about it. This lack of awareness can be due to women feeling embarrassed or just not reporting their symptoms. It is important to remember that vaginal dryness is not a little annoyance or something to dismiss. GSM can significantly affect physical comfort, intimate relationships, self-confidence, and overall quality of life. You do not have to suffer in silence. The reason GSM occurs is simple. Estrogen plays a critical role in maintaining the health of vaginal and urinary tissues. As estrogen declines during menopause, these tissues can become thinner, drier, and less elastic, leading to symptoms that affect both intimacy and everyday comfort. Unfortunately, many women assume these changes are just a normal part of aging that they must accept. That isn't true. Effective treatments are available, and the first step is talking to a healthcare provider who understands menopause care. That's where Midi Health can help. Midi specializes in caring for women during midlife and menopause, including conditions like GSM that are often overlooked or undertreated. Their clinicians help women understand what's happening in their bodies, discuss treatment options, and develop personalized care plans. Depending on a woman's symptoms and medical history, they may include vaginal estrogen therapy, non-hormonal treatments, moisturizers, lubricants, or other evidence-based approaches designed to improve comfort and quality of life. Just as importantly, Midi provides a supportive environment where conversations about your symptoms are taken seriously, not dismissed or minimized. The good news is that relief is possible and women don't have to just tolerate these symptoms. Go to joinmidi.com. Joinmidi.com and connect with one of their clinicians today. This episode is brought to you by Whoop, the wearable health and fitness coach that gives you personalized insights into your sleep, recovery, strain, and overall health so you can empower your day. Whoop keeps things intentional by staying screen-free. It won't buzz you to hit a step count, but rather works alongside a companion app to deliver clear, actionable physiological data. With membership tiers like Whoop 1 for everyday performance, Whoop Peak for long-term wellness, and Whoop Life for medical-grade insights, there's a fit for every goal. Lately, I've been spending a lot of time in Colorado hiking and getting outside whenever I can. And with how much I travel for work and how busy my schedule can get, I'm always looking for ways to better understand how my body is responding to everything I'm asking of it. That's where I think something like the Whoop 5.0 wearable could be really helpful. It could give me insights into my sleep, recovery, and strain, whether I'm hiking in Colorado, traveling for work, or simply trying to keep up with a busy week. It can help me recognize when I have the energy to push myself and when my body might be telling me it's time to slow down and prioritize recovery. To learn more, head to whoop.com.
Let's talk about the conglomerate because I saw someone testifying in Congress and they had a, you know, a board popped up and it was... I didn't realize. Walk me through a CVS, right? You know, and all the touch points they have in the healthcare system.
The largest of them has more than 3,000 subsidiaries. They do more than $160 billion a year of intercompany transfers, meaning they work with those 3,000 subsidiaries in every way they can.
What's in the subsidiaries?
Um, it might be like for CVS, they own Aetna, the insurance company. You know, it might be the CVS pharmacies. It might be Caremark, which is their pharmacy benefit manager that works with your employer. Um, it might be, I forget the name of their third-party administrator who works on the medical side and makes the drugs that are infused at a hospital or a clinic more expensive. And so they always default to paying their own subsidiaries more, particularly in a world of the ACA where there's this thing called medical loss ratio where they have to spend at least 85% of their premiums on healthcare. Well, if you pay a subsidiary doctor, clinic, pharmacy more, you reach that threshold, the 85% threshold, much more quickly. And on the alternate side, you get to keep that margin in your subsidiary company. So, it's left pocket, right pocket. And then at the pharmacy level, they charge to market whatever they can get away with. I mean, that's normal business. I mean, I'm not mad at them, but you know, again, that's the difference with costplusdrugs.com because it's the same price for everybody. No matter what city, what state, what time of day, it doesn't matter. It's the same price.
You mentioned the PBM, pharmacy benefit manager. What is that? And that was not a term I'd heard of until probably about a year ago. You start popping up on my feed talking about this. Explain to our listeners, right, who these people are and who they work for.
What's a pharmacy benefit manager? Um, it's just what it implies. When your employer, if you get your insurance through your employment, or if you get your insurance through the ACA, or if you get Medicare, traditional Medicare, and you buy Part D supplemental insurance, my parents... The company that manages the pharmacy benefit is called a pharmacy benefit manager. And their job originally was to just process claims. You know, hey, I need my... I got a prescription. When I show up at the drugstore, they have my prescription and somebody needs to process that to make sure everybody gets paid. Okay? That's what it was originally meant to do. Okay? Then because in doing that they were able to build up a formulary, you know, the list of drugs that's available to you in your insurance plan. Because they were able to build up tens of millions of lives each, they were put in a dominant position where they basically controlled how much volume any manufacturer would get. You know, so if you're on the formulary to the exclusion of your competition, you were in a great position. Well, the pharmacy benefit managers realized that they could charge the manufacturers for access to that formulary. And that's where you hear these discussions of rebates and everything going on. Now, they would tell you they offer all these other clinical services and everything. I'm not a big fan of that. I'd rather get my clinical services from doctors rather than insurance conglomerates. Um, but that's what they do. They process claims. They go out and negotiate pricing and they make determinations of how much you're going to pay as a plan holder.
Wow. Um, does the way that PBMs pay for generics, does that lead to shortages?
Um, it's not so much how they pay for generics. It's more how affiliated companies of theirs structure their purchasing. So CVS is a partner with a company called Red Oak and they go out and together they purchase a lot of generics, probably purchase at a lot lower cost than we do at Cost Plus Drugs, but they retain a lot of that margin. And then because they have to set up a network of pharmacies who want access to all the lives they cover, the plan holders they cover, they tell the pharmacies, 'We're only going to reimburse you X amount of money for your generic prescriptions that you fill,' and by definition that's going to make them more expensive in certain circumstances.
Women in menopause are, you know, experiencing besides the shortage, and we'll go back to that in a second, but it's, you know, that's mostly our listeners are women in menopause. Um, but I think it happens across the board where suddenly everything's covered, you're doing great, you've got your meds, and then boom, it's a new year.
Oh, yeah. Yeah. And things change.
And things change. You can't get it. You can't find it. I know my kids' ADHD meds was a scramble, you know, to try to find their medications because things are coming off and on formularies. Is that even legal?
It's legal, unfortunately. Because what happens is the insurance company that designs the plan and works with or is owned by the pharmacy benefit manager says, 'Wow, things changed in HRT. We're getting a lot more patients that are expecting us to use the premium money that they paid us or that their employer paid us. Well, we're spending a lot more and it's so popular. We can charge them more.' And again, they're too big to care. Their mission is to make money. When you, you know, they're public companies and when you listen to them talking to Wall Street, you don't ever hear them say, 'Well, our volumes are going up, so our price is going to go down to patients.' You hear them say, 'Business is great. We have the opportunity to raise prices, so we're going to do that because we're going to make more money.' That's our fiduciary responsibility to their shareholders. But at the same time, the laws are changing so that the PBMs that they own are now being defined as fiduciaries to the employer that they're hired by. And the employer has a fiduciary responsibility to the health and wellness of their employees or their members, employees and their families. And so while these prices have gone up, there's an opportunity for employers, in particular self-insured employers, to respond to this and take their fiduciary responsibility and say no to the PBMs. And that's where I spend a big part of my time is trying to educate CEOs that it's your money. You did hire this conglomerate to manage all the claims and set the pricing, but at the end of the day, you want the women in your company or the wives or the daughters or the mothers to be as healthy as possible. I mean, that's why you have insurance in the first place. And so, a lot of these rules are evolving now and changing right now and the employers lag behind.
Cost Plus Drugs pricing, where Canadians have to buy out of pocket. Most drugs, if it's made available in a hospital in Canada, you don't have to pay out of pocket. If it's not prescribed out of a hospital, and the rules are changing, you do have to pay out of pocket. And so we're cheaper than Canadian drugs. In Germany, there's some of the same things, other countries. So Cost Plus Drugs, we have people from all around the world trying to buy from us. We can't sell to them. So on the generic side, which is 92% of the prescriptions, the US is cheaper. And you know, I'm proud to say that Cost Plus has played a big role in that. On the brand side, we're a lot more expensive. On the specialty drugs, on the cell and gene therapy, we're a lot more expensive. Part of that, I would say, and I'm guessing 70 to 80% of that is middlemen increasing the price. If you took out the middlemen, the pricing structures would change and prices would go down.
Why is... walk me through that.
So if you want the inside baseball... Yeah. Okay. So when a brand medication... so say we get a female testosterone approved, pretend, and it's a brand, right?
It's going to be a brand. So let's just say it's a $600 testosterone. I don't know what a good price is. I don't know. I'm trying to use... just pretend it's $600. This is meant to use easy math. Yeah. And so it's $600 list price. The manufacturer probably has to pay rebates to the pharmacy benefit managers in order to be on their formula. Okay? Otherwise, they're going to say... for the privilege of like having it on the formulary so they can sell it.
Literally, I had a conversation yesterday with a company that sells Qutenza, which is a non-opioid pain medication. Yeah. And you know, they told me that the PBMs that they talked to, and all of them basically, all the big ones, the big three, told them that unless they raised the price, and I forget what their exact price is, but it's under $200, but unless they raised it to $700, with most of that being rebate, not only would they not put them on the formulary, but they will block them otherwise. That's the way this industry works.
And so if you have a testosterone that's supposed to be $600, again pulling numbers out of the air, what ends up happening now is the manufacturer... there's three big wholesalers, too. There's three big pharmacy benefit managers and three big distributors that, in the case of the wholesalers, control 95% of the transactions in pharmacy. You would think they'd be big enough as multi-hundred billion dollar companies each to go and negotiate a great price. But what ends up happening for brand medications is they'll say, um, the brand will say to them, 'Okay, we'll give you 5% off.'
Okay, that's kind of weird. Um, but okay, so now it's $570 to the distributor. How can they sell to pharmacies? They can't sell for less than $570, right? Otherwise, they'd be losing money. So now, anybody who walks into a pharmacy for that testosterone is going to pay at least $570. And if you don't have insurance or you have a high deductible or you're in your deductible phase, you're probably paying $570 to $600.
Now, here comes the crazy part. The manufacturer of that brand testosterone isn't making $570. They are only making $300, to use easy numbers. Why is there a discrepancy between the 570 and the 300? Because they have to take that delta and pay it to the pharmacy benefit managers in order to get placed on those formularies and not exclude it.
So that's the middleman you're talking about.
That's the middleman, right? So if we were in a good system, what would end up happening is that brand manufacturer, the testosterone, would say, 'Look, um, in the old system, I would make $300. I'm going to sell it to this distributor for $310.' And the distributor was previously making $30. So they're going to sell it to the pharmacies for $340. They're going to make more. But now the pharmacies are only paying $340 instead of $570. So they can sell to every patient for $230 less.
And that is the delta you see between what happens here in the United States versus what happens out in the rest of the world. And it's another reason why the prices of brand medications are so high. And the crazier part is when I talk to the CEOs of these brand companies and I say, 'Why do you do this? You have all these patients who can't afford it for the reasons we mentioned, can't adhere to it if they were able to afford it once.' Right.
Why are you not doing it this other way that is the more efficient and better for everybody way? And they say to me, they're like, 'Mark, we literally get threatened by the pharmacy benefit managers who are part of these big conglomerates that if we don't play by these rules, they will remove not just this drug from that formulary, but all of our portfolio.'
All right. When a generic goes short, who gets served first? So, whoever's hustling on the back end, like if CVS or Walgreens or Mark Cuban or...
When a generic goes on short supply, it really depends who the manufacturer is and who they have relationships with.
And how did you... how were you... you have patches in supply?
Because we're telling our manufacturers, more, more, more, more, more. We need as much as you can make and we'll pay you a little bit more. And so that's why you saw we had one really low price and then we basically sold all they could make. So, we went to a manufacturer who charged us more, but I just felt... I made a decision. I just felt that, you know, when we got the low-cost patches in, then people... they would be available to people, but I wanted to have a supply even if it was more expensive.